

# Peihua Luo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5542673/publications.pdf>

Version: 2024-02-01

42  
papers

973  
citations

361413

20  
h-index

477307

29  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1458  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. <i>Autophagy</i> , 2022, 18, 1152-1173.	9.1	16
2	Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors. <i>Bioorganic Chemistry</i> , 2022, 121, 105673.	4.1	5
3	Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib. <i>Biochemical Pharmacology</i> , 2022, 201, 115105.	4.4	3
4	PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). <i>Autophagy</i> , 2021, 17, 3221-3237.	9.1	33
5	Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. <i>Toxicology Letters</i> , 2021, 338, 1-9.	0.8	5
6	Regulation of p53 stability as a therapeutic strategy for cancer. <i>Biochemical Pharmacology</i> , 2021, 185, 114407.	4.4	27
7	Discovery of <i>N</i> -((3 <i>S</i> ,4 <i>S</i> )-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 <i>H</i> -pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12163-12180.	6.4	14
8	Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112115.	5.6	28
9	Hepatotoxicity of FDA-approved small molecule kinase inhibitors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 335-348.	2.4	7
10	Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112297.	5.6	4
11	Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1311-1325.	3.3	5
12	Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. <i>Toxicology Letters</i> , 2020, 319, 102-110.	0.8	6
13	A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 891.	3.5	48
14	COVID-19 epidemic: a special focus on diagnosis, complications, and management. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1085-1093.	3.1	2
15	&lt;p&gt;Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	4.3	80
16	Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. <i>European Journal of Pharmacology</i> , 2020, 874, 173022.	3.5	8
17	Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory. <i>European Journal of Pharmacology</i> , 2020, 874, 173026.	3.5	29
18	s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced handâ€‘foot skin reaction that can be reversed by nicotinamide. <i>Cell Research</i> , 2020, 30, 779-793.	12.0	24

#	ARTICLE	IF	CITATIONS
19	ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. <i>Toxicology and Applied Pharmacology</i> , 2019, 383, 114768.	2.8	30
20	Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1121-1127.	3.1	24
21	Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 767-774.	3.3	58
22	Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis. <i>European Journal of Pharmacology</i> , 2019, 847, 26-31.	3.5	22
23	Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis. <i>Toxicology and Applied Pharmacology</i> , 2019, 366, 10-16.	2.8	44
24	Vascular endothelial growth factor (<scp>VEGF</scp>) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (<scp>MKI</scp>s): A systematic literature review and meta-analysis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 659-667.	1.9	7
25	HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy. <i>Toxicology Letters</i> , 2018, 292, 115-122.	0.8	42
26	HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. <i>Autophagy</i> , 2018, 14, 2155-2170.	9.1	34
27	High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity. <i>Toxicology Letters</i> , 2018, 296, 39-47.	0.8	37
28	Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. <i>British Journal of Cancer</i> , 2017, 116, 1027-1036.	6.4	26
29	The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. <i>Environmental Toxicology and Pharmacology</i> , 2017, 49, 81-88.	4.0	22
30	Design, Synthesis and Evaluation of Indene Derivatives as Retinoic Acid Receptor $\beta$ Agonists. <i>Molecules</i> , 2017, 22, 32.	3.8	6
31	All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RAR $\beta$ -mediated DNA damage. <i>BMC Cancer</i> , 2016, 16, 2.	2.6	8
32	Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress. <i>Toxicology Reports</i> , 2016, 3, 78-86.	3.3	15
33	Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair. <i>PLoS ONE</i> , 2016, 11, e0146968.	2.5	21
34	Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor. <i>Molecular Medicine Reports</i> , 2015, 11, 3842-3847.	2.4	4
35	Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling. <i>Oncotarget</i> , 2015, 6, 6203-6217.	1.8	27
36	Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. <i>Oncotarget</i> , 2015, 6, 3254-3267.	1.8	55

#	ARTICLE	IF	CITATIONS
37	Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway. <i>Toxicology and Applied Pharmacology</i> , 2014, 274, 319-327.	2.8	21
38	Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. <i>Toxicology and Applied Pharmacology</i> , 2012, 261, 280-291.	2.8	67
39	The Proteasome Inhibitor Bortezomib Enhances ATRA-Induced Differentiation of Neuroblastoma Cells via the JNK Mitogen-Activated Protein Kinase Pathway. <i>PLoS ONE</i> , 2011, 6, e27298.	2.5	16
40	Inhibition of all- <i>Trans</i> -retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. <i>Molecular Carcinogenesis</i> , 2011, 50, 24-35.	2.7	21
41	Bortezomib induces apoptosis in human neuroblastoma CHP126 cells. <i>Die Pharmazie</i> , 2010, 65, 213-8.	0.5	3
42	Function of retinoid acid receptor $\hat{\pm}$ and p21 in all- <i>trans</i> -retinoic acid-induced acute T-lymphoblastic leukemia apoptosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1183-1189.	1.3	19